一种用于慢性淋巴细胞白血病的口服药物。
An oral drug for chronic lymphocytic leukemia.
机构信息
Amber Koehler practices in this Division of Hematology at the Mayo Clinic in Rochester, Minn., and is an assistant professor of medicine in the Mayo Clinic College of Medicine. The author has disclosed no potential conflicts of interest, financial or otherwise.
出版信息
JAAPA. 2020 Feb;33(2):51-53. doi: 10.1097/01.JAA.0000651764.99857.a5.
Ibrutinib is a new first-line drug for treating chronic lymphocytic leukemia (CLL), and could change frontline treatment of CLL from traditional IV chemotherapy to oral targeted therapy. Lymphocytosis often worsens with initiation of ibrutinib, but typically resolves over 6 to 18 months. Though patients generally tolerate ibrutinib well, the drug can cause adverse reactions including hypertension, atrial fibrillation, bleeding, and infections such as fungal pneumonia.
伊布替尼是一种治疗慢性淋巴细胞白血病（CLL）的新型一线药物，它可能将 CLL 的一线治疗从传统 IV 化疗转变为口服靶向治疗。伊布替尼起始治疗时通常会导致淋巴细胞增多，但通常会在 6 至 18 个月内缓解。尽管患者通常能很好地耐受伊布替尼，但该药物可引起不良反应，包括高血压、心房颤动、出血和真菌感染如肺孢子菌肺炎等。
Zotero 插件